Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value

Author:

Xie Yafei12,Wei Yujie12,Li Dan12,Pu Jie12,Ding Hong2,Zhang Xiaowei12ORCID

Affiliation:

1. Lanzhou University Second College of Clinical Medicine, Lanzhou University, Lanzhou, China; and

2. Department of Cardiology, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China.

Abstract

Abstract: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used to treat diabetes mellitus. Abundant evidence has shown that SGLT2 inhibitors can reduce hospitalization for heart failure (HF) in patients with or without diabetes. An increasing number of studies are being conducted on the mechanisms of action of SGLT2 inhibitors in HF. Our review summarizes a series of clinical trials on the cardioprotective effects of SGLT2 inhibitors in the treatment of HF. We have summarized several classical SGLT2 inhibitors in cardioprotection research, including empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, and sotagliflozin. In addition, we provided a brief overview of the safety and benefits of SGLT2 inhibitors. Finally, we focused on the mechanisms of SGLT2 inhibitors in the treatment of HF, including ion-exchange regulation, volume regulation, ventricular remodeling, and cardiac energy metabolism. Exploring the mechanisms of SGLT2 inhibitors has provided insight into repurposing these diabetic drugs for the treatment of HF.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Pharmacology

Reference154 articles.

1. Heart disease and stroke statistics-2021 update: a report from the American Heart Association;Virani;Circulation,2021

2. Epidemiology of heart failure: a contemporary perspective;Roger;Circ Res.,2021

3. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American Heart Association Joint Committee on clinical practice guidelines;Heidenreich;Circulation,2022

4. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: a systematic review and network meta-analysis of randomized clinical trials;Bao;Pharmacol Res.,2021

5. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association;Heidenreich;Circ Heart Fail.,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3